CYNAERA Institute - Long COVID Library
Analyzing One of the Most Impactful Illnesses of Our Lifetime
Long COVID affects millions, yet remains undercounted, inconsistently recognized, and structurally mismanaged across healthcare, research, labor, education, and public policy. Updated 2026 CYNAERA US-CCUC™ prevalence modeling suggests that corrected U.S. Long COVID prevalence realistically falls between 48.5–64.6 million adults, with a default baseline of approximately 65 million when accounting for diagnostic delay, reinfections, surveillance gaps, fluctuating disability status, hidden severe cases, and overlapping infection associated chronic conditions.
This library offers one of the most advanced visibility and systems frameworks in the world, designed to correct diagnostic failure, burden underestimation, institutional delay, and structural blind spots in real time. Explore how CYNAERA’s AI engines, predictive algorithms, and state-dependent modeling systems are transforming how Long COVID is researched. Integrating environmental burden, flare dynamics, viral persistence, and system stability to improve both safety and long-term effectiveness in treatments.
Journal and Conference Recognition
CYNAERA’s Long COVID Library is anchored by public research outputs that examine both the current burden of Long COVID and future treatment pathways for post-infectious chronic disease. The SSRN preprint, “One New Long COVID Case Every Minute in the United States,” estimates ongoing Long COVID incidence using public surveillance anchors and the CYNAERA US-CCUC™ framework.
CYNAERA’s Long COVID treatment modeling has also entered international scientific review through CRISPRMED26, a leading conference focused on genomic medicine, gene editing, and translational therapeutics. The abstract, “CRISPR Remission: A Flare-Aware Gene Editing Pathway Engine for Immune-Volatile Chronic Disease,” presents a gene-editing treatment pathway for immune-volatile chronic diseases such as Long COVID, where timing, flare dynamics, immune stability, patient heterogeneity, and biologic readiness may determine whether advanced therapeutics can be deployed safely and effectively. Together, these external anchors position the Long COVID Library as a structured research hub for Long COVID incidence, disease burden, immune volatility, flare-aware treatment design, and future therapeutic readiness.
Long COVID Research Library
Prevalence & Demographic Factors
Study Design & Stratification
Catalyst, Progression and Flares
Tech + Blood-Based Diagnostics
Treatments & Therapeutics
-
Therapeutic Polarity in Long COVID and ME/CFS
Why CYNAERA Chose Long COVID
CYNAERA’s Long COVID work did not begin as an academic exercise. It began because COVID changed my family’s life permanently. I nearly died from Long COVID. My son developed Long COVID as a young child. Multiple members of my family have experienced serious disability and life-altering health decline after COVID infection, with the number affected and the severity of impact continuing to grow over time.
Long COVID made visible what institutions were still unwilling to confront: infection can permanently reshape lives, families, workforce stability, education, and long-term health trajectories. The problem was never limited to one patient or one diagnosis. It was structural, compounding, and vastly undercounted.
This library was built from lived survival, research, policy work, and the recognition that existing systems were failing to measure the real burden, detect patterns early, protect vulnerable families, or respond with the urgency this crisis demands. It exists to make Long COVID legible where medicine, public health, and policy have too often minimized, fragmented, or ignored it. This is not a library of detached documents. It is a living intelligence structure built from direct experience, systems analysis, and the refusal to let millions remain unseen.
Upcoming Library Expansions
CYNAERA is actively expanding into adjacent terrain conditions where diagnostic lag and physician education deficits reduce quality of life for patients:
POTS (Postural Orthostatic Tachycardia Syndrome)
Genetic vs. infection-onset logic, school dropout forecasts, and access mapping.
MCAS (Mast Cell Activation Syndrome)
Air quality interaction modules, anaphylaxis risk terrain, and treatment audits.
PANS/PANDAS
Pediatric neuroimmune modeling, early detection, parent guides, psychiatric misdiagnosis detection, and IEP pipeline mapping.
Fibromyalgia & Gulf War Illness
Cluster mapping, symptom fingerprinting, and VA-specific diagnostic logic.
Cancer Risk and Terrain Forecasting
Long-term immune instability, post-infectious burden, and upstream oncologic terrain forecasting through CRATE™.